ERBB2 and breast carcinoma: Among various subtypes of breast cancer, overexpression and amplification of the human epidermal growth factor receptor type 2 (HER2; ErbB2/neu) accounts for about 20% of all cases and is a predictor of aggressive phenotype and poor prognosis [1].